Arbutus Biopharma (NASDAQ:ABUS – Get Free Report) and YD Bio (NASDAQ:YDES – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, dividends and analyst recommendations.
Insider & Institutional Ownership
43.8% of Arbutus Biopharma shares are owned by institutional investors. 19.9% of Arbutus Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Analyst Ratings
This is a breakdown of recent recommendations and price targets for Arbutus Biopharma and YD Bio, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Arbutus Biopharma | 1 | 0 | 1 | 0 | 2.00 |
| YD Bio | 1 | 0 | 0 | 0 | 1.00 |
Profitability
This table compares Arbutus Biopharma and YD Bio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Arbutus Biopharma | 83.95% | 129.32% | 112.24% |
| YD Bio | N/A | N/A | N/A |
Valuation and Earnings
This table compares Arbutus Biopharma and YD Bio”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Arbutus Biopharma | $14.08 million | 64.47 | -$33.50 million | $0.83 | 5.54 |
| YD Bio | $596,817.00 | 300.09 | N/A | N/A | N/A |
YD Bio has lower revenue, but higher earnings than Arbutus Biopharma.
Summary
Arbutus Biopharma beats YD Bio on 9 of the 10 factors compared between the two stocks.
About Arbutus Biopharma
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company’s research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients’ HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
About YD Bio
YD Bio Limited is a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations.
Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
